Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
DISHMAN PHARMA | LUPIN | DISHMAN PHARMA/ LUPIN |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | -294.7 | - | View Chart |
P/BV | x | 3.3 | 3.8 | 87.2% | View Chart |
Dividend Yield | % | 0.7 | 0.6 | 117.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
LUPIN Mar-20 |
DISHMAN PHARMA/ LUPIN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 882 | 42.4% | |
Low | Rs | 129 | 505 | 25.5% | |
Sales per share (Unadj.) | Rs | 197.8 | 339.4 | 58.3% | |
Earnings per share (Unadj.) | Rs | 21.2 | -5.9 | -356.6% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 15.5 | 224.4% | |
Dividends per share (Unadj.) | Rs | 2.00 | 6.00 | 33.3% | |
Dividend yield (eoy) | % | 0.8 | 0.9 | 91.9% | |
Book value per share (Unadj.) | Rs | 179.9 | 276.7 | 65.0% | |
Shares outstanding (eoy) | m | 80.69 | 453.00 | 17.8% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 1.3 | 2.0 | 62.3% | |
Avg P/E ratio | x | 11.9 | -116.6 | -10.2% | |
P/CF ratio (eoy) | x | 7.2 | 44.8 | 16.2% | |
Price / Book Value ratio | x | 1.4 | 2.5 | 55.8% | |
Dividend payout | % | 9.4 | -100.9 | -9.3% | |
Avg Mkt Cap | Rs m | 20,306 | 314,201 | 6.5% | |
No. of employees | `000 | 0.8 | 18.3 | 4.5% | |
Total wages/salary | Rs m | 5,355 | 29,868 | 17.9% | |
Avg. sales/employee | Rs Th | 19,252.7 | 8,400.6 | 229.2% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,632.0 | 395.8% | |
Avg. net profit/employee | Rs Th | 2,064.1 | -147.2 | -1,402.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 153,748 | 10.4% | |
Other income | Rs m | 265 | 4,838 | 5.5% | |
Total revenues | Rs m | 16,226 | 158,585 | 10.2% | |
Gross profit | Rs m | 4,103 | 24,849 | 16.5% | |
Depreciation | Rs m | 1,091 | 9,702 | 11.2% | |
Interest | Rs m | 944 | 3,630 | 26.0% | |
Profit before tax | Rs m | 2,334 | 16,355 | 14.3% | |
Minority Interest | Rs m | 0 | 4 | 0.0% | |
Prior Period Items | Rs m | 1 | 39 | 2.8% | |
Extraordinary Inc (Exp) | Rs m | 0 | -7,521 | 0.0% | |
Tax | Rs m | 624 | 11,571 | 5.4% | |
Profit after tax | Rs m | 1,711 | -2,694 | -63.5% | |
Gross profit margin | % | 25.7 | 16.2 | 159.1% | |
Effective tax rate | % | 26.7 | 70.8 | 37.8% | |
Net profit margin | % | 10.7 | -1.8 | -611.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 154,132 | 7.1% | |
Current liabilities | Rs m | 9,517 | 92,252 | 10.3% | |
Net working cap to sales | % | 9.4 | 40.2 | 23.4% | |
Current ratio | x | 1.2 | 1.7 | 69.3% | |
Inventory Days | Days | 110 | 82 | 134.6% | |
Debtors Days | Days | 35 | 129 | 26.9% | |
Net fixed assets | Rs m | 16,304 | 89,082 | 18.3% | |
Share capital | Rs m | 161 | 906 | 17.8% | |
"Free" reserves | Rs m | 12,907 | 124,461 | 10.4% | |
Net worth | Rs m | 14,516 | 125,367 | 11.6% | |
Long term debt | Rs m | 4,189 | 17,933 | 23.4% | |
Total assets | Rs m | 29,805 | 249,839 | 11.9% | |
Interest coverage | x | 3.5 | 5.5 | 63.0% | |
Debt to equity ratio | x | 0.3 | 0.1 | 201.8% | |
Sales to assets ratio | x | 0.5 | 0.6 | 87.0% | |
Return on assets | % | 8.9 | 0.4 | 2,378.4% | |
Return on equity | % | 11.8 | -2.1 | -548.6% | |
Return on capital | % | 17.5 | 8.7 | 200.9% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 51,450 | 9.6% | |
Fx outflow | Rs m | 697 | 19,470 | 3.6% | |
Net fx | Rs m | 4,255 | 31,980 | 13.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 14,688 | 19.0% | |
From Investments | Rs m | -1,529 | 11,070 | -13.8% | |
From Financial Activity | Rs m | -941 | -8,906 | 10.6% | |
Net Cashflow | Rs m | 316 | 16,853 | 1.9% |
Indian Promoters | % | 61.4 | 46.6 | 131.8% | |
Foreign collaborators | % | 0.0 | 0.2 | - | |
Indian inst/Mut Fund | % | 3.7 | 11.3 | 32.7% | |
FIIs | % | 12.7 | 31.9 | 39.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 10.1 | 218.8% | |
Shareholders | 46,261 | 98,259 | 47.1% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: UNICHEM LAB AUROBINDO PHARMA STERLING BIOTECH GLENMARK PHARMA VENUS REMEDIES
Compare DISHMAN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.
Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.
For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.
For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.
For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More